Colorectal Cancer: Zaltrap Efficacy for BRAF and RAS Mutations

Colorectal Cancer: Zaltrap Efficacy for BRAF and RAS Mutations

Colorectal Cancer: Zaltrap Efficacy for BRAF and RAS Mutations

• August 21, 2017
• Reading time: 1 minute

This article discusses WCG 2017 findings regarding Aflibercept (brand name: Zaltrap, known as Soft Cancer Arrest Injection in Taiwan), a second-line therapy for colorectal cancer. This drug shows higher efficacy in patients with BRAF gene mutations or RAS wild-type gene mutations.

Presented by Dr. Sabine Tejpar from University Hospital Leuven, Belgium, at the ESMO 19th Gastrointestinal Cancer Conference (WCGC2017) held June 28-July 1 in Barcelona, Spain. This analysis examined tumor markers and assessed DNA/RNA from patient samples across 591 participants.

For KRAS gene exon2 wild-type analysis (281 patients), the median overall survival (OS) was 11.6 months (95% CI: 10.5-15.9) in the placebo group and 14.9 months (95% CI: 12.4-18.0) in the Zaltrap group.

For KRAS gene exon2 mutation (201 patients), median OS was 10.6 months (95% CI: 8.1-14.0) in the placebo group and 12.6 months (95% CI: 10.2-14.5) in the Zaltrap group.

For RAS wild-type analysis (218 patients), median OS was 11.7 months (95% CI: 10.1-15.9) in the placebo group and 16.0 months (95% CI: 12.7-22.8) in the Zaltrap group.

For BRAF wild-type analysis (446 patients), median OS was 12.4 months (95% CI: 10.7-15.1) in the placebo group and 13.0 months (95% CI: 12.4-15.9) in the Zaltrap group.

For BRAF gene mutation (36 patients), median OS was 5.5 months (95% CI: 3.5-10.6) in the placebo group and 10.3 months (95% CI: 5.3-NA) in the Zaltrap group.

According to Dr. Tejpar, for advanced colorectal cancer with BRAF mutations receiving second-line therapy, the median OS of 10.3 months in the Zaltrap group exceeds that observed with EGFR antibody medications.

#Colorectal Cancer

• Clinical Trial Drug

  (Lung Cancer) Topotecan and Topotecan + Berzosertib Show Promising Results in Phase II Trial. (Lung Cancer) HER2 Gene Mutation Non-Small Cell Lung Cancer: Is Enhertu Effective? (Lung Cancer) Is Anti-B7-H3 Antibody DS-7300 Effective?

Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4